Prof. Paul W.H.I. Parren is dedicated to translating antibody biology and immunotherapy knowledge into innovative therapeutics and technologies. He holds a PhD in molecular immunology from the University of Amsterdam (1992) and was an Associate Professor at The Scripps Research Institute. He led research and preclinical development at Genmab, leading to seven product approvals to date and is an inventor of multiple drugs and two clinically translated technologies.
He is a tenured Professor of Molecular Immunology at the Leiden University Medical Center. In 2018, he joined LAVA Therapeutics, a biotechnology company that discovers and develops bispecific gamma-delta T cell engagers from its Gammabody platform to transform cancer therapy, as its Executive Vice President and Head of R&D. He also provides drug development, patent and investment advice as an independent consultant from his company Sparring Bioconsult. He is currently the chair of the Board of Directors for The Antibody Society, an international non-profit trade organization involved in antibody research and development.